A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with ...

Comprehensive Cancer Center and Departments of Internal Medicine, Pharmacology, and Medicinal Chemistry, and Life Sciences Institute, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, ...

Objective: In this study, our aim was to search for new genotype-phenotype correlations in patients with Von Hippel-Lindau (VHL) disease. This study was approved by the Ethics Committee of the Clinics ...

⊥ Institute of Pharmaceutical Chemistry, Johann Wolfgang Goethe-University and Buchmann Institute for Molecular Life Sciences, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany *Tel.: +44-1273 ...

An independent validation was performed on 914 patients. Nonmutational p53 dysfunction identifies MDS with poor outcomes that are not efficiently captured by conventional prognostic scores. These ...

Many functions have been assigned to the von Hippel‐Lindau tumor suppressor gene product (pVHL), including targeting the alpha subunits of the heterodimeric transcription factor HIF (hypoxia‐inducible ...

Cohort A1 of LITESPARK-015 trial included patients with advanced PPGL, cohort A2 included patients with pancreatic neuroendocrine tumors (pNETs), cohort B1 included patients with von Hippel-Lindau ...

Belzutifan has become the first FDA-approved oral therapy for pheochromocytoma or paraganglioma. The objective response rate (ORR) for belzutifan in patients with ...

NTS071 is an oral small molecule allosteric reactivator targeting p53 Y220C with a novel scaffold. It selectively binds to the p53 Y220C mutant protein, improving its thermal stability, thereby ...